These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16779276)

  • 1. Automatic detection of spironolactone - related adverse drug events.
    Huang C; Noirot LA; Reichley RM; Bouselli DA; Dunagan WC; Bailey TC
    AMIA Annu Symp Proc; 2005; 2005():989. PubMed ID: 16779276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Life-threatening hyperkalemia: a potentially lethal drug combination.
    Juvet T; Gourineni VC; Ravi S; Zarich SW
    Conn Med; 2013 Sep; 77(8):491-3. PubMed ID: 24156179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
    Hauben M; Reich L; Gerrits CM
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
    Erden I; Yalcin S; Ozhan H
    Kardiol Pol; 2010 Sep; 68(9):1043-5; discussion 1046. PubMed ID: 20859899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.
    Fujii H; Nakahama H; Yoshihara F; Nakamura S; Inenaga T; Kawano Y
    Kobe J Med Sci; 2005; 51(1-2):1-6. PubMed ID: 16199929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrocardiogram changes in hyperkalemia: there and back again.
    Zimlichman E; Liran O
    Isr Med Assoc J; 2005 Nov; 7(11):748. PubMed ID: 16309005
    [No Abstract]   [Full Text] [Related]  

  • 8. [Drug-related hyperkalemia resulted from spironolactone and angiotensin converting enzyme inhibitors therapy].
    Dutka M; Dzielski T; Wojciechowska J; Heller L; Trybus M
    Pol Merkur Lekarski; 1999 Aug; 7(38):69-70. PubMed ID: 10522422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone.
    Berry C; McMurray J
    Am J Med; 2001 Nov; 111(7):587. PubMed ID: 11705445
    [No Abstract]   [Full Text] [Related]  

  • 10. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
    Juurlink DN; Mamdani MM; Lee DS; Kopp A; Austin PC; Laupacis A; Redelmeier DA
    N Engl J Med; 2004 Aug; 351(6):543-51. PubMed ID: 15295047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Spironolactone and potassium].
    Kjeldsen K
    Ugeskr Laeger; 2004 Nov; 166(48):4392; author reply 4392-3. PubMed ID: 15587639
    [No Abstract]   [Full Text] [Related]  

  • 12. Heart failure drug poses potassium problems. When using "the water pill" spironolactone, watch your potassium intake and check your levels.
    Harv Heart Lett; 2004 Dec; 15(4):3. PubMed ID: 15704264
    [No Abstract]   [Full Text] [Related]  

  • 13. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
    Muzzarelli S; Maeder MT; Toggweiler S; Rickli H; Nietlispach F; Julius B; Burkard T; Pfisterer ME; Brunner-La Rocca HP;
    Am J Cardiol; 2012 Mar; 109(5):693-8. PubMed ID: 22152974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
    Goland S; Naugolny V; Korbut Z; Rozen I; Caspi A; Malnick S
    Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
    Shah KB; Rao K; Sawyer R; Gottlieb SS
    J Am Coll Cardiol; 2005 Sep; 46(5):845-9. PubMed ID: 16139135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Life-threatening, preventable hyperkalemia in a nursing home resident: case report and literature review.
    Dharmarajan TS; Nguyen T; Russell RO
    J Am Med Dir Assoc; 2005; 6(6):400-5. PubMed ID: 16286062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure. A retrospective analysis of 125 consecutive cases].
    Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
    Ugeskr Laeger; 2004 Sep; 166(37):3201-3. PubMed ID: 15384373
    [No Abstract]   [Full Text] [Related]  

  • 18. [Late drug-induced hyperkalemia in a patient with congestive heart failure].
    Konopa J; Bułło B; Rutkowski B
    Przegl Lek; 2005; 62(7):732-3. PubMed ID: 16463712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases.
    Wrenger E; Müller R; Moesenthin M; Welte T; Frölich JC; Neumann KH
    BMJ; 2003 Jul; 327(7407):147-9. PubMed ID: 12869459
    [No Abstract]   [Full Text] [Related]  

  • 20. Factors predicting hyperkalemia in patients with cirrhosis receiving spironolactone.
    Abbas Z; Mumtaz K; Salam A; Jafri W
    J Coll Physicians Surg Pak; 2003 Jul; 13(7):382-4. PubMed ID: 12887837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.